Exercise and Acarbose in Type 2 Diabetes

Effect of Exercise Training - Alone or in Combination With Acarbose - on Clinical and Metabolic Factors, and Studies of Cellular and Moleculargenetic Factors, in Type 2 Diabetes.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01244971

Enrollment

Registered

2010-11-22

Start date

2004-01-31

Completion date

Unknown

Last updated

2010-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Type 2

Brief summary

The purpose of this study is to investigate the impact of exercise training, Acarbose, and the combination of exercise and Acarbose on glycemic control, body composition, insulin sensitivity and other cardiovascular risk markers in type 2 diabetes. Further, muscle biopsies will be obtain to study gene expression. Our hypothesis is that the combination therapy will be superior to monotherapy with exercise or Acarbose.

Interventions

DRUGAcarbose

100mg, 3 times daily

BEHAVIORALExercise

Moderate combined exercise, 50 minutes 3 times per week

OTHERExercise + Acarbose

See respective monotherapy description

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

45 Years to 60 Years

Inclusion criteria

Men and women, diagnosis of type 2 diabetes established since at least three months, treatment with diet or maximum one oral anti-diabetic drug, GHb \< 8.5 %, age 45 - 60 years, BMI 25 - 30 kg/m2, no participation in any regular exercise program. \-

Exclusion criteria

Unable to perform exercise, significant GI-disease, severe heart-disease, renal failure \-

Design outcomes

Primary

Measure	Time frame	Description
Glycemic control	12 weeks	Glycated A1c

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026